.
BioEnterprise

Orca Pharmaceuticals Could Receive Up to $122.5 Million in Deal With AstraZeneca

Orca Pharmaceuticals, a portfolio company of Cleveland-based BioMotiv, and AstraZeneca announced a partnership to develop inhibitors against a wide range of autoimmune diseases. Orca will receive upfront and milestone payments from AstraZeneca with a potential total value of $122.5 million.

Read More  >